company background image
CPRX

Catalyst Pharmaceuticals NasdaqCM:CPRX Stock Report

Last Price

US$17.27

Market Cap

US$1.8b

7D

1.8%

1Y

151.7%

Updated

04 Dec, 2022

Data

Company Financials +
CPRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance5/6
Financial Health6/6
Dividends0/6

CPRX Stock Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

Catalyst Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Catalyst Pharmaceuticals
Historical stock prices
Current Share PriceUS$17.27
52 Week HighUS$18.39
52 Week LowUS$5.24
Beta1.27
1 Month Change23.53%
3 Month Change25.60%
1 Year Change151.75%
3 Year Change269.81%
5 Year Change331.75%
Change since IPO183.12%

Recent News & Updates

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11
Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Recent updates

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11
Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Is Interesting

Nov 03
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Is Interesting

Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Low P/E No Reason For Excitement

Mar 30
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Low P/E No Reason For Excitement

Does Catalyst Pharmaceuticals (NASDAQ:CPRX) Deserve A Spot On Your Watchlist?

Mar 09
Does Catalyst Pharmaceuticals (NASDAQ:CPRX) Deserve A Spot On Your Watchlist?

We're Not Counting On Catalyst Pharmaceuticals (NASDAQ:CPRX) To Sustain Its Statutory Profitability

Feb 11
We're Not Counting On Catalyst Pharmaceuticals (NASDAQ:CPRX) To Sustain Its Statutory Profitability

Could The Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Ownership Structure Tell Us Something Useful?

Jan 21
Could The Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Ownership Structure Tell Us Something Useful?

Is Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's Recent Performance A Reflection Of Its Financial Health?

Dec 27
Is Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's Recent Performance A Reflection Of Its Financial Health?

Our View On Catalyst Pharmaceuticals' (NASDAQ:CPRX) CEO Pay

Dec 06
Our View On Catalyst Pharmaceuticals' (NASDAQ:CPRX) CEO Pay

Shareholder Returns

CPRXUS BiotechsUS Market
7D1.8%4.2%1.5%
1Y151.7%-7.4%-14.9%

Return vs Industry: CPRX exceeded the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: CPRX exceeded the US Market which returned -14.9% over the past year.

Price Volatility

Is CPRX's price volatile compared to industry and market?
CPRX volatility
CPRX Average Weekly Movement8.5%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: CPRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CPRX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200276Pat McEnanyhttps://www.catalystpharma.com

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies.

Catalyst Pharmaceuticals, Inc. Fundamentals Summary

How do Catalyst Pharmaceuticals's earnings and revenue compare to its market cap?
CPRX fundamental statistics
Market CapUS$1.80b
Earnings (TTM)US$66.92m
Revenue (TTM)US$191.76m

26.9x

P/E Ratio

9.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CPRX income statement (TTM)
RevenueUS$191.76m
Cost of RevenueUS$47.60m
Gross ProfitUS$144.16m
Other ExpensesUS$77.24m
EarningsUS$66.92m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.64
Gross Margin75.18%
Net Profit Margin34.90%
Debt/Equity Ratio0%

How did CPRX perform over the long term?

See historical performance and comparison